A randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjogrens syndrome

Trial Profile

A randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjogrens syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Sjogren's syndrome
  • Focus Therapeutic Use
  • Acronyms TRACTISS
  • Most Recent Events

    • 17 Jun 2017 Results (n=66) of substudy presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 10 Mar 2017 Primary endpoint (Visual Analogue Scale: achievement of a 30% reduction at 48 weeks from baseline in either oral dryness or fatigue measured using patient-completed visual analogue scales) has not been met, according to results published in the Arthritis and Rheumatology Journal.
    • 10 Mar 2017 Results of clinical efficacy and cost-effective analysis of rituximab, published in the Arthritis and Rheumatology Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top